Innovent Biologics has dosed the first participant in GLORY-3, a Phase 3 trial comparing mazdutide 9 mg to semaglutide 2.4 mg in Chinese adults with overweight/obesity and metabolic dysfunction-associated fatty liver disease.
Altimmune announced plans to initiate Phase II trials of its GLP-1/glucagon agonist pemvidutide for alcohol use disorder in Q2 2025 and alcohol-related liver disease in Q3, expanding beyond obesity treatment.
Innovent Biologics announced that mazdutide, a novel GLP-1R/GCGR dual agonist, successfully met all primary and key secondary endpoints in the GLORY-1 Phase 3 trial for weight management in Chinese adults with overweight or obesity.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.